How is colloid milium treated?
Colloid milium is a rare, benign dermatosis characterized by small, translucent, yellowish-brown papules that result from the extracellular deposition of abnormal colloid material—primarily altered elastin and collagen—in the upper dermis. It most commonly affects sun-exposed areas such as the face, dorsal hands, and forearms, and is strongly associated with chronic ultraviolet (UV) radiation exposure, particularly in fair-skinned individuals. Other potential contributing factors include arsenic exposure, renal disease, and certain connective tissue disorders.
Treatment remains challenging due to the deep dermal location of the colloid deposits and their resistance to conventional therapies. There is no universally effective or FDA-approved treatment; management is largely individualized and often focuses on cosmetic improvement. First-line approaches may include topical retinoids (e.g., tretinoin) for mild cases, though evidence of efficacy is limited. Physical modalities—such as cryotherapy, electrodessication, dermabrasion, and CO₂ or Er:YAG laser ablation—have shown variable success, with lasers offering more precise removal and potentially better cosmetic outcomes. However, recurrence is common, especially without strict photoprotection.
Crucially, rigorous sun avoidance and broad-spectrum sunscreen use (SPF 50+, UVA/UVB protection) are essential components of both prevention and long-term management. Patients should also be evaluated for underlying systemic conditions—particularly chronic kidney disease or prior arsenic exposure—if clinical suspicion arises. Referral to a board-certified dermatologist with expertise in pigmentary and connective tissue disorders is recommended for accurate diagnosis (often confirmed via skin biopsy showing periodic acid–Schiff [PAS]-positive, diastase-resistant colloid deposits) and tailored therapeutic planning.